Title: "Overview of the Car-T Program at the MUHC"
Speaker: Dr. Michael Sebag, MD, PhD, FRCPC

Educational Objectives:
Getting familiar with CarT cells in hematologic oncologies. Discussing the future applications of CarT therapies. Learning the processes that were established for regulatory and safety purposes. Reviewing our institution’s outcomes.

Biosketch:
Medical school: University of Toronto
PhD: McGill University in Physiology
Residency in Internal Medicine followed by Hematology and Oncology and a fellowship at the Mayo Clinic in Multiple Myeloma.
Active in preclinical translational research in Myeloma as well as in clinical research ranging from investigator initiated studies and Phase I trials. More recently, medical director of the immune effector cell therapy center at the MUHC.

свернуть